Overview

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Status:
Completed

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of treatment with VX-371 in hypertonic saline compared to hypertonic saline alone in subjects with cystic fibrosis (CF) who are ≥12 years of age, homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation, and being treated with Orkambi

Phase:

Phase 2

Details

Lead Sponsor:

Parion Sciences
Vertex Pharmaceuticals Incorporated

Collaborator:

Vertex Pharmaceuticals Incorporated

Treatments:

Ivacaftor